Trial · NCT02967302
NEUROIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the Knee Joint
NCT02967302, Phase 2, Phase 3, Unknown, Hildrun Haibel
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NEUROIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the Knee Joint. Trials, record NCT02967302. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02967302
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NEUROIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the Knee Joint
- NCT number
- NCT02967302
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 112 participants, estimated
- Lead sponsor
- Hildrun Haibel
- Conditions
- Knee Arthritis
- Interventions
- Morphine Sulfate, Triamcinolone, placebo
- First posted
- 2016-11-18
- Last updated
- 2021-08-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction of pain intensity (on a 100mm VAS) at 8 a.m. on day 7 compared to baseline | 1 week | Reduction of pain intensity (on a 100mm VAS) at 8 a.m. on day 7 compared to baseline |
| Secondary | Area under the VAS curve (AUC) of VAS pain during the first week until 8 p.m. on day 7 | 1 week | Area under the VAS curve (AUC) of VAS pain during the first week until 8 p.m. on day 7 |
| Secondary | Pain intensity on McGill pain questionnaire (MPQ) at baseline, week 1 and 2 | 2 weeks | Pain intensity on McGill pain questionnaire (MPQ) at baseline, week 1 and 2 |
| Secondary | daily activities at baseline, week 1 and 2 | 2 weeks | daily activities at baseline, week 1 and 2 |
| Secondary | activity and mobility of the knee joint (Lysholm Gilquist-Score) at baseline, week 1 and 2 | 2 weeks | activity and mobility of the knee joint (Lysholm Gilquist-Score) at baseline, week 1 and 2 |
| Secondary | WOMAC scale (before i.a. injections at baseline, week 1 and 2) | 2 weeks | WOMAC scale (before i.a. injections and at the end of each week) |
| Secondary | nflammatory parameters (cellular infiltrate, opioid receptors and peptides, IL-17, TNFα) in synovial biopsies and fluid (before i.a. medication at baseline and week 1), | 1 weeks | nflammatory parameters (cellular infiltrate, opioid receptors and peptides, IL-17, TNFα) in synovial biopsies and fluid (before and 7 days af-ter i.a. medication), |
| Secondary | supplementary analgesic consumption continuously in the patients diary, recorded at week 1 and 2 | 2 weeks | supplementary analgesic consumption continuously in the patients diary, recorded at week 1 and 2 |
| Secondary | Any systemic (e.g. nausea, sedation) and local side effects (infection, tissue injury) will be recorded continuously in the patients diary, recorded at week 1 and week 2. | Screening, Baseline, week 1, week 2 | Any systemic (e.g. nausea, sedation) and local side effects (infection, tissue injury) will be recorded continuously in the patients diary, recorded at week 1 and 2. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02967302
GET https://conductscience.org/api/trials/v1/NCT02967302/registered